Methods and compositions for rapidly decreasing epigenetic age and restoration of more youthful function
View Patent ↗Disclosed are methods and compositions of reducing the epigenetic age of mammalian organism, especially an adult human of geriatric age. The methods provide for the proliferation of endogenous stem cells using mitochondrial fusion and a UCP2 blocker or other stimulants; supplying stem cells with nutrition to prevent cell cycle arrest; and removal of senescent somatic cells using senolytic treatments. The proliferation of endogenous neural stem cells after plaque removal for the treatment of Alzheimer's is also disclosed.
1. A method for decreasing the epigenetic age of a mammalian organism having epigenetically old somatic cells and epigenetically young stem cells, comprising the steps:
(a) endogenously stimulating mitochondria of said epigenetically young stem cells to a fusion state;
(b) endogenously stimulating proliferation of at least a portion of said epigenetically young stem cells from step (a) into daughter stem cells; and
(c) repeating steps (a) and (b) at least once after a delay for stem cell maturation.
2. The method as recited in claim 1 , wherein step (a) comprises supplying a therapeutically effective oral dose of stearic acid and/or sulforaphane source.
3. The method as recited in claim 1 , wherein step (b) comprises supplying a therapeutically effective dose of a UCP2 blocker.
4. The method as recited in claim 2 , wherein step (b) comprises supplying a therapeutically effective dose of C60 dissolved in oil.
5. The method as recited in claim 1 , wherein step (b) comprises delivering a therapeutically effective dose of nutrition to said epigenetically young stem cells.
6. The method as recited in claim 5 , wherein said therapeutically effective dose of nutrition comprises methionine.
7. The method as recited in claim 6 , wherein said therapeutically effective dose of nutrition further comprises leucine and lysine.
8. The method as recited in claim 1 , further comprising:
(d) stimulating apoptosis of at least a portion of epigenetically old somatic cells.
9. The method as recited in claim 8 , wherein step (d) comprises supplying a therapeutically effective oral dose of a mitochondrial fission agent.
10. The method as recited in claim 8 , wherein step (d) comprises dosing with a therapeutically effective amount of at least two from a group consisting of: apigenin, fisetin, curcumin, quercetin, resveratrol, dasatinib, navitoclax, piperlongumine, and a butyrate source.
11. The method as recited in claim 9 , wherein said mitochondrial fission agent comprises an oxidized nicotinamide adenine dinucleotide (NAD + ) promoter, and/or apigenin.
12. The method as recited in claim 11 , wherein the NAD + promoter is selected from one or more of a group consisting of: niacin; nicotinamide; nicotinamide riboside; nicotinamide and ribose; niacin and ribose; nicotinamide mononucleotide; and oxidized nicotinamide adenine dinucleotide.